Skip to main content

Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.

Publication ,  Journal Article
Chang, L-L; Schneider, SM; Chiang, S-C; Horng, C-F
Published in: Cancer nursing
May 2013

Several studies have documented the efficacy of prophylactic granulocyte colony-stimulating factor in reducing rates of infections and risk of febrile neutropenia. An appropriate risk assessment model is pivotal to identify high-risk patients who would require granulocyte colony-stimulating factor prophylaxis.The objectives of the study were to develop, implement, and evaluate a risk assessment model for neutropenic events in breast cancer patients who were receiving myelosuppressive chemotherapy.During the study period, neutropenia risk was assessed for breast cancer patients by using an innovative risk model before the first cycle of chemotherapy. A stepwise logistic regression model was performed to determine significant factors for the prediction.A total of 119 patients were evaluated for neutropenia risk between August 2010 and December 2010. Twenty-nine percent (35/119) of the patients have experienced at least 1 neutropenic event during the initial 3 cycles of chemotherapy. Based on the logistic regression model, only the risk score was retained as the significant predictor; the probability of an individual patient developing neutropenic events increased 1.24 times by increasing 1 score number (odds ratio, 1.24; with 95% confidence interval, 1.063-1.457).Based on the examination of different cutoff points, the performance of the risk model is best when the risk threshold is set at 6, which was found to have a sensitivity of 0.49 and a specificity of 0.69; the misclassification rate was 0.37, with a positive predictive value of 0.40 and a negative predictive value of 0.76.The results of this project support incorporating the discussed risk assessment model into routine nursing assessments to prevent neutropenic complications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer nursing

DOI

EISSN

1538-9804

ISSN

0162-220X

Publication Date

May 2013

Volume

36

Issue

3

Start / End Page

198 / 205

Related Subject Headings

  • Sensitivity and Specificity
  • Risk Factors
  • Risk Assessment
  • Predictive Value of Tests
  • Nursing
  • Neutropenia
  • Middle Aged
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chang, L.-L., Schneider, S. M., Chiang, S.-C., & Horng, C.-F. (2013). Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. Cancer Nursing, 36(3), 198–205. https://doi.org/10.1097/ncc.0b013e3182642d98
Chang, Li-Lu, Susan M. Schneider, Shao-Chin Chiang, and Cheng-Fang Horng. “Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.Cancer Nursing 36, no. 3 (May 2013): 198–205. https://doi.org/10.1097/ncc.0b013e3182642d98.
Chang L-L, Schneider SM, Chiang S-C, Horng C-F. Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. Cancer nursing. 2013 May;36(3):198–205.
Chang, Li-Lu, et al. “Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer.Cancer Nursing, vol. 36, no. 3, May 2013, pp. 198–205. Epmc, doi:10.1097/ncc.0b013e3182642d98.
Chang L-L, Schneider SM, Chiang S-C, Horng C-F. Implementing an evidence-based risk assessment tool to predict chemotherapy-induced neutropenia in women with breast cancer. Cancer nursing. 2013 May;36(3):198–205.

Published In

Cancer nursing

DOI

EISSN

1538-9804

ISSN

0162-220X

Publication Date

May 2013

Volume

36

Issue

3

Start / End Page

198 / 205

Related Subject Headings

  • Sensitivity and Specificity
  • Risk Factors
  • Risk Assessment
  • Predictive Value of Tests
  • Nursing
  • Neutropenia
  • Middle Aged
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Female